Skip to content

Continuous Femoral Block With Levobupivacaine 0.125% or Ropivacaine 0.2% in Elderly Patients With Femoral Fractures

Comparison Between Continuous Femoral Block With Levobupivacaine 0.125% and Ropivacaine 0.2% for Preoperative Analgesia, in Patients Over 70 Years Old, With Proximal Femoral Fractures: a Randomized, Double-blind Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03815565
Enrollment
70
Registered
2019-01-24
Start date
2017-08-28
Completion date
2021-01-08
Last updated
2020-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femur Fracture, Hip Fractures

Keywords

analgesia, continuous, femoral block

Brief summary

This study evaluates the continuous femoral block between levobupivacaine 0.125% and ropivacaine 0.2% in patients with proximal femoral fracture.These patients will be divided into 2 groups of 35 patients, one L group (levobupivacaine 0.125%) and one R group (ropivacaine 0.2%) distributed randomly, receiving continuous infusion through patient controlled analgesia (PCA) pump with the following parameters: infusion 5 ml / h, bolus 5 ml, lockout 30 min.

Detailed description

Pain is associated with neurohormonal stress, myocardial ischemia and delayed mobilization, thus being able to increase the hospitalization time and associated with increased postoperative mortality. Regional anesthesia through simple or continuous femoral nerve block are options for analgesia in patients with femoral fracture, as well as analgesia by venous opioids. A potential benefit of regional anesthesia is precisely to avoid the use of opioids and other general anesthetics, which in turn are also closely related to postoperative delirium. Continuous femoral block, since the preoperative period, is associated with the reduction of acute pain and opioid consumption, in patients with femoral neck fractures. There are few studies available in the literature comparing analgesic equipotency between levobupivacaine and ropivacaine in peripheral nerve blocks. In none of them, the peripheral analgesia in the femoral nerve, for proximal femoral fracture was compared.

Interventions

PROCEDUREcontinuous femoral block

infusion of anesthetic by PCA pump

Sponsors

Hospital Municipal Miguel Couto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

Only the pharmacist chief knows which participant belongs to each arm

Intervention model description

randomized

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 70 years old or more * patients with femur fracture * physical status risk American Society of Anesthesiologists (ASA) P1 - P3

Exclusion criteria

* physical status ASA P4 * patients with BMI \> 35 * systemic infection * Injury or infection at the site of installation of the femoral perineural catheter * Catheter displacement of the perineural site * Montreal Cognitive Assessment (MoCA) \< 26 * Patients operated before 24 hours of hospital admission

Design outcomes

Primary

MeasureTime frameDescription
intensity of individual pain episodes6 hours after hospital admissionSelf report pain intensity in the preoperative period. Scored 0-10 (0 = no pain; 10 = pain as bad as can be)

Secondary

MeasureTime frameDescription
Number of PCA firing72 hoursin each patient at time of evaluation of pain
Degree of satisfaction with analgesic therapyup to 72 hours - at the moment of surgery; or at the end of 72 hoursusing the 5-point rating scale (very dissatisfied, dissatisfied, neutral, satisfied or very pleased)
Quality of sleepup to 72 hoursvery good, good, bad and very bad
the cost of analgesic therapyup to 72 hoursincluding catheters, PCA and medication in each patient
adverse eventup to 72 hoursparesthesia, nausea, vomiting, ringing in the ear, metallic taste, convulsion or cardiac arrest

Countries

Brazil

Contacts

Primary ContactRafael Linhares
rafaellinhares@me.com+55 21 981436088
Backup ContactIsmar Cavalcanti
ismarcavalcanti@gmail.com+55 21 999822993

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026